CLINICAL TRIALS PROFILE FOR MERIDIA
✉ Email this page to a colleague
All Clinical Trials for Meridia
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00234832 ↗ | A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients | Completed | Abbott | Phase 3 | 2003-01-01 | The purpose of the study was to determine the long-term effect of sibutramine treatment on cardiovascular outcomes in overweight and obese patients at risk of a cardiovascular event. |
| NCT00234988 ↗ | A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects. | Completed | Abbott | Phase 4 | 2004-06-01 | The purpose of the study is to determine the safety and weight loss when sibutramine is used in overweight and obese subjects. |
| NCT00261911 ↗ | A Study of Sibutramine in Overweight Adolescents to Assess Weight Loss and Safety. | Completed | Abbott | Phase 3 | 2000-07-01 | The purpose of this study is to assess the effectiveness of sibutramine on weight loss, reduction in body size and improvement in metabolic risk factors and safety in obese adolescents. |
| NCT00402077 ↗ | A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects | Completed | AstraZeneca | Phase 2 | 2006-11-01 | This study will examine the safety, tolerability, and body weight effect of subcutaneous pramlintide alone and in various combinations with the oral antiobesity agents sibutramine or phentermine in overweight and obese subjects. |
| NCT00402584 ↗ | A Study to Examine the Efficacy and Safety of Meridia® (Sibutramine Hydrochloride) in Binge-Eating Disorder | Completed | Abbott | Phase 3 | 2000-08-01 | The purpose of this study is to examine the safety and efficacy of sibutramine in preventing binge eating episodes. Additionally the study aim is to evaluate the safety and efficacy of sibutramine in reducing body weight in subjects with binge-eating disorder. |
| NCT00433641 ↗ | Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes | Completed | National Institutes of Health (NIH) | Phase 4 | 2006-07-01 | Control of food intake, size and frequency of meals are critical to the development of obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in control of calorie intake. It is unclear whether the approved appetite reducing drug sibutramine changes the function of the stomach. Differences in the way individuals respond to treatment with the appetite suppressant sibutramine may also explain why some people lose weight while others do not. In a previous study of 48 overweight or obese participants, we preliminarily observed that variation in the gene for the promoter of the serotonin transporter protein was significantly associated with degree of weight loss. This new single center clinical study aims to evaluate the effects of the FDA-approved appetite suppressing medication, sibutramine (MERIDIA)on weight loss and stomach emptying in patients who are overweight or obese. The effect of individual differences in inherited genes that modify serrotonin and noradrenergic receptors on weight reduction with sibutramine will be tested. |
| NCT00433641 ↗ | Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes | Completed | Mayo Clinic | Phase 4 | 2006-07-01 | Control of food intake, size and frequency of meals are critical to the development of obesity. The stomach signals feelings of fullness after a meal and therefore plays a role in control of calorie intake. It is unclear whether the approved appetite reducing drug sibutramine changes the function of the stomach. Differences in the way individuals respond to treatment with the appetite suppressant sibutramine may also explain why some people lose weight while others do not. In a previous study of 48 overweight or obese participants, we preliminarily observed that variation in the gene for the promoter of the serotonin transporter protein was significantly associated with degree of weight loss. This new single center clinical study aims to evaluate the effects of the FDA-approved appetite suppressing medication, sibutramine (MERIDIA)on weight loss and stomach emptying in patients who are overweight or obese. The effect of individual differences in inherited genes that modify serrotonin and noradrenergic receptors on weight reduction with sibutramine will be tested. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Meridia
Condition Name
Clinical Trial Locations for Meridia
Trials by Country
Clinical Trial Progress for Meridia
Clinical Trial Phase
Clinical Trial Sponsors for Meridia
Sponsor Name
